½ÃÀ庸°í¼­
»óǰÄÚµå
1619310

È£Èí±â Áúȯ °Ë»ç ½ÃÀå ±Ô¸ð, Á¡À¯À², ¼ºÀå ºÐ¼®, °Ë»ç À¯Çüº°, ¿ëµµº°, Áö¿ªº° - »ê¾÷º° ¿¹Ãø(2024-2031³â)

Respiratory Disease Testing Market Size, Share, Growth Analysis, By Test Type (Mechanical Tests, Imaging Tests), By Application (Lung Cancer, Asthma), By Region - Industry Forecast 2024-2031

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: SkyQuest | ÆäÀÌÁö Á¤º¸: ¿µ¹® 157 Pages | ¹è¼Û¾È³» : 3-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

È£Èí±â Áúȯ °Ë»ç ¼¼°è ½ÃÀå ±Ô¸ð´Â 2022³â 61¾ï 7,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. ½ÃÀåÀº 2023³â 63¾ï 4,000¸¸ ´Þ·¯¿¡¼­ 2031³â 78¾ï 4,000¸¸ ´Þ·¯¿¡ À̸£°í, ¿¹Ãø ±â°£(2024-2031³â) µ¿¾È 2.7%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

¼¼°è È£Èí±â Áúȯ °Ë»ç ½ÃÀåÀº õ½Ä, COPD, Æó¾Ï µî È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í °øÇØ, Èí¿¬, °í·ÉÈ­ µîÀ¸·Î ÀÎÇØ ¾ÇÈ­µÇ°í ÀÖ´Â °¡¿îµ¥ °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ºÐÀÚÁø´Ü, ¸é¿ª ÃøÁ¤, ¿µ»ó Áø´ÜÀÇ ±â¼ú ¹ßÀü¿¡ ÈûÀÔ¾î °Ë»ç È¿À²¼º°ú °Ë»ç °á°ú°¡ °³¼±µÇ¸é¼­ Á¤È®ÇÑ Áø´Ü ¹æ¹ý¿¡ ´ëÇÑ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖÀ¸¸ç, Äڷγª19 ÆÒµ¥¹ÍÀº È£Èí±â °Ë»çÀÇ Á߿伺À» ´õ¿í ºÎ°¢½Ã۸ç PCR°ú Ç׿ø °Ë»ç¸¦ Æ÷ÇÔÇÑ ´Ù¾çÇÑ °Ë»ç ¹æ¹ý¿¡ ´ëÇÑ ¼ö¿ä¸¦ °ßÀÎÇß½À´Ï´Ù. ±×·¯³ª ³ôÀº °Ë»ç ºñ¿ë, ÀÎ½Ä ºÎÁ·, ƯÈ÷ °³¹ßµµ»ó±¹ÀÇ ºÎÁ·ÇÑ ÀÎÇÁ¶ó·Î ÀÎÇØ Àú¼Òµæ Áö¿ªÀÇ Á¢±Ù¼ºÀ» Á¦ÇÑÇÏ´Â ¹®Á¦µµ ³²¾ÆÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±ÔÁ¦ À庮ÀÌ ±â¼ú Çõ½Å°ú Á¦Ç° Ãâ½Ã¿¡ °É¸²µ¹ÀÌ µÉ ¼ö ÀÖÀ¸¸ç, ȯÀÚ Ä¡·á¿¡¼­ °Ë»çÀÇ Áß¿äÇÑ ¿ªÇÒ¿¡ ´ëÇÑ ÀÌÇØ¸¦ ³ôÀ̱â À§ÇÑ ±³À°Àû ÀÌ´Ï¼ÅÆ¼ºêÀÇ Çʿ伺ÀÌ °­Á¶µÇ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

¼­·Ð

  • Á¶»ç ¸ñÀû
  • Á¶»ç ¹üÀ§
  • Á¤ÀÇ

Á¶»ç ¹æ¹ý

  • Á¤º¸ Á¶´Þ
  • 2Â÷ µ¥ÀÌÅÍ¿Í 1Â÷ µ¥ÀÌÅÍ ¹æ¹ý
  • ½ÃÀå ±Ô¸ð ¿¹Ãø
  • ½ÃÀå ÀüÁ¦Á¶°Ç°ú Á¦ÇÑ

ÁÖ¿ä ¿ä¾à

  • ¼¼°è ½ÃÀå Àü¸Á
  • °ø±Þ°ú ¼ö¿ä µ¿Ç⠺м®
  • ºÎ¹®º° ±âȸ ºÐ¼®

½ÃÀå ¿ªÇаú Àü¸Á

  • ½ÃÀå °³¿ä
  • ½ÃÀå ±Ô¸ð
  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀΰú ±âȸ
    • ¼ºÀå ¾ïÁ¦¿äÀΰú °úÁ¦
  • PorterÀÇ Five Forces ºÐ¼®

ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®

  • Áß¿ä ¼º°ø ¿äÀÎ
  • °æÀï Á¤µµ
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ½ÃÀå »ýŰè
  • ½ÃÀåÀÇ ¸Å·Â Áö¼ö(2023³â)
  • PESTEL ºÐ¼®
  • °Å½Ã°æÁ¦ ÁöÇ¥
  • ¹ë·ùüÀÎ ºÐ¼®
  • °¡°Ý ºÐ¼®
  • ±â¼ú Áøº¸
  • ±ÔÁ¦ »óȲ
  • »ç·Ê ¿¬±¸

È£Èí±âÁúȯ °Ë»ç ½ÃÀå ±Ô¸ð : °Ë»ç À¯Çüº°

  • ½ÃÀå °³¿ä
  • ±â°è ½ÃÇè
    • Spirometry
    • Peak-Flow Test
    • Pulmonary Function Test
    • Blood Gas Test
    • ±âŸ
  • ¿µ»ó °Ë»ç
    • X¼±
    • CT ½ºÄµ
    • ÃÊÀ½ÆÄ °Ë»ç
    • MRI
  • ü¿ÜÁø´Ü °Ë»ç
    • POC(Point of Care) Å×½ºÆ®
    • ºÐÀÚÁø´Ü °Ë»ç

È£Èí±âÁúȯ °Ë»ç ½ÃÀå ±Ô¸ð : ¿ëµµº°

  • ½ÃÀå °³¿ä
  • ¸¸¼º Æó¼â¼º ÆóÁúȯ
  • Æó¾Ï
  • õ½Ä
  • °áÇÙ
  • ±âŸ

È£Èí±âÁúȯ °Ë»ç ½ÃÀå ±Ô¸ð : ÃÖÁ¾ ¿ëµµº°

  • ½ÃÀå °³¿ä
  • º´¿ø
  • ÀÇ»ç Ŭ¸®´Ð
  • ÀÓ»ó ½ÇÇè½Ç

È£Èí±âÁúȯ °Ë»ç ½ÃÀå ±Ô¸ð : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ½ºÆäÀÎ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • GCC ±¹°¡
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

°æÀï Á¤º¸

  • ÁÖ¿ä 5°³»ç ºñ±³
  • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´×(2023³â)
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÌ Ã¤ÅÃÇÑ Àü·«
  • ½ÃÀå ÃÖ±Ù µ¿Çâ
  • ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • ±â¾÷ °³¿ä
    • Á¦Ç° Æ÷Æ®Æú¸®¿À ºÐ¼®
    • ºÎ¹®º° Á¡À¯À² ºÐ¼®
    • ¸ÅÃâ Àü³â´ëºñ ºñ±³(2021-2023³â)

ÁÖ¿ä ±â¾÷ °³¿ä

  • Beckton Dickinson and Company
  • Koninklijke Philips N.V.
  • ResMed Inc.
  • Medtronic
  • MG Diagnostic Corporation
  • Abbott
  • ThermoFisher Scientific
  • Biomerieux
  • QIAGEN
  • Seimens Healthineers AG
  • F. Hoffmann-La Roche Ltd
  • SDI Diagnostics
  • BD
  • Niterra Co., Ltd.
  • QuantuMDx Group Ltd.
  • COSMED srl
  • Bird Healthcare
  • visby medical
  • Seegene Inc
  • Bio-Rad Laboratories Inc

°á·Ð°ú Ãßõ »çÇ×

LSH 25.01.10

Global Respiratory Disease Testing Market size was valued at USD 6.17 billion in 2022 and is poised to grow from USD 6.34 billion in 2023 to USD 7.84 billion by 2031, growing at a CAGR of 2.7% during the forecast period (2024-2031).

The global respiratory disease testing market has witnessed robust growth, fueled by the rising prevalence of respiratory conditions like asthma, COPD, and lung cancer, exacerbated by pollution, smoking, and aging populations. The urgency for accurate diagnostic methods has escalated, supported by technological advancements in molecular diagnostics, immunoassays, and imaging, which enhance testing efficiency and outcomes. The COVID-19 pandemic further underscored the importance of respiratory testing, driving demand for diverse testing methods, including PCR and antigen tests. However, challenges remain, including high testing costs limiting access in low-income areas, awareness deficits, and inadequate infrastructure, particularly in developing regions. Additionally, regulatory hurdles may impede innovation and product launches, emphasizing the need for educational initiatives to enhance understanding of testing's critical role in patient care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Respiratory Disease Testing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Respiratory Disease Testing Market Segmental Analysis

Global Respiratory Disease Testing Market is segmented by test type, application, end-use and region. Based on test type, the market is segmented into mechanical tests, imaging tests and in-vitro diagnostic tests. Based on application, the market is segmented into chronic obstructive pulmonary disease, lung cancer, asthma, tuberculosis and other. Based on end-use, the market is segmented into hospital, physicians clinic and clinical laboratories. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Respiratory Disease Testing Market

The global respiratory disease testing market is primarily driven by the escalating incidence of respiratory conditions like asthma, chronic obstructive pulmonary disease (COPD), and lung cancer. Contributing factors such as environmental pollution, tobacco use, and an aging population are exacerbating the prevalence of these diseases worldwide. This surge in respiratory health issues underscores the urgent necessity for reliable and effective testing solutions, prompting healthcare providers and patients alike to seek out advanced diagnostic tools. As the demand for precise testing continues to rise, the respiratory disease testing market is expected to experience significant growth in response to these pressing public health challenges.

Restraints in the Global Respiratory Disease Testing Market

The Global Respiratory Disease Testing market faces significant restraints due to rigorous regulatory approval processes. The complexity involved in navigating these regulations can create substantial hurdles for market participants. Securing the necessary approvals for new testing technologies often requires extensive time and financial resources, resulting in prolonged delays for product launches. This situation not only stifles innovation but also restricts the ability of companies to introduce cutting-edge solutions to the market. Consequently, the challenging regulatory landscape may inhibit the overall growth and advancement of the respiratory disease testing sector, limiting potential improvements in patient care and disease management.

Market Trends of the Global Respiratory Disease Testing Market

The Global Respiratory Disease Testing market is witnessing a notable trend towards increased emphasis on point-of-care testing (POCT), which facilitates swift diagnosis and immediate treatment decisions directly at the patient's location. This surge in demand is largely fueled by the need for rapid and precise results, particularly within critical care environments and resource-constrained areas, where traditional laboratory testing may be less feasible. As healthcare providers prioritize quick turnaround times to enhance patient outcomes, the adoption of innovative point-of-care testing devices and platforms is expected to rise significantly, marking a transformative shift in respiratory disease management and testing approaches globally.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2023
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Technological Advancement
  • Regulatory Landscape
  • Case Studies

Global Respiratory Disease Testing Market Size by Test Type & CAGR (2024-2031)

  • Market Overview
  • Mechanical Tests
    • Spirometry
    • Peak-Flow Test
    • Pulmonary Function Test
    • Blood Gas Test
    • Others
  • Imaging Tests
    • X-Ray
    • Ct-Scan
    • Ultrasonography
    • Mri
  • In-Vitro Diagnostic Tests
    • Point-Of-Care Test
    • Molecular Diagnostic Test

Global Respiratory Disease Testing Market Size by Application & CAGR (2024-2031)

  • Market Overview
  • Chronic Obstructive Pulmonary Disease
  • Lung Cancer
  • Asthma
  • Tuberculosis
  • Other

Global Respiratory Disease Testing Market Size by End-Use & CAGR (2024-2031)

  • Market Overview
  • Hospital
  • Physicians Clinic
  • Clinical Laboratories

Global Respiratory Disease Testing Market Size & CAGR (2024-2031)

  • North America (Test Type, Application, End-Use)
    • USA
    • Canada
  • Europe (Test Type, Application, End-Use)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Test Type, Application, End-Use)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Test Type, Application, End-Use)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Test Type, Application, End-Use)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2023
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2023
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

  • Beckton Dickinson and Company
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Koninklijke Philips N.V.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • ResMed Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Medtronic
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • MG Diagnostic Corporation
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Abbott
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • ThermoFisher Scientific
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biomerieux
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • QIAGEN
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Seimens Healthineers AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • F. Hoffmann-La Roche Ltd
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • SDI Diagnostics
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • BD
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Niterra Co., Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • QuantuMDx Group Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • COSMED srl
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bird Healthcare
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • visby medical
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Seegene Inc
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bio-Rad Laboratories Inc
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendation

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦